Recently, agonistic PD-1 antibody treatment diminished the atherosclerosis development in Ldlr−/− mice, enhancing atheroprotective B and CD4+ T cell responses (Grievink et al., 2021[26]). Here, PDCD1 is linked to atherosclerosis.